STERIS (STE) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
STERIS plc (STE) insider buying and selling: no purchases, 10 sales
69 Form 4 Table I transactions filed with the SEC by STERIS plc insiders between 2025-10-03 and 2026-10-05 (15-month history): 0 open-market purchases and 10 sales, plus 59 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $4.0M by Zangerle John Adam on 2025-11-11.
STERIS insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, STERIS insiders filed 9 sales worth $9.8M on the open market, and no purchases.
The biggest seller was Zangerle John Adam (Sr. VP, Gen Counsel, and Sec.): $4.3M in 2 sales, out of 7 different sellers.
The largest trade of the period was a sale of $4.0M on Nov 11, 2025, by Zangerle John Adam (Sr. VP, Gen Counsel, and Sec.). Form 4 on sec.gov (0001628280-25-052076).
Of the 9 sales, 3 (33%, $1.2M) carry the 10b5-1 plan flag on the Form 4, meaning they were scheduled months ahead; the other 6 do not.
The last three months show 1 sale, against 4 in the three before. The latest sale from Aug 12, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. STERIS has more sales than 29 of the other 58, ranks 36 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with STE's sales, largest first. The full history is in the tool above, already searched.
See all 69 STE trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-11-11 | 2025-11-13 | Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | $4.0M | S — Open-market sale2 Form 4 footnotesF2 Price reflects a weighted average sale price for multiple transactions ranging from $265.00 to $265.95 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 As of November 11, 2025, 8,511 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,157 on June 1, 2026; 846 on June 2, 2026; 1,252 on June 3, 2026; 1,376 on June 4, 2026; 1,252 on June 3 2027; 1,376 on June 4, 2027 and 1,252 on June 5, 2028. | SEC |
| 2025-11-21 | 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | $1.3M | S — Open-market saleForm 4 footnoteF1 As of November 21, 2025, 4,003 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 578 on June 1, 2026, 352 on June 2, 2026; 666 on June 3, 2026; 542 on June 4, 2026; 666 on June 3, 2027; 542 on June 4, 2027 and 666 on June 5, 2028. | SEC |
| 2025-11-18 | 2025-11-20 | Tamaro Renato | V.P. & Corporate Treasurer | $1.3M | S — Open-market sale3 Form 4 footnotesF2 Price reflects a weighted average sale price for multiple transactions ranging from $257.01 to $257.87 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F1 As of November 18, 2025, 1,475 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 241 on June 1, 2026; 141 on June 2, 2026; 217 on June 3, 2026; 221 on June 4, 2026; 217 on June 3, 2027; 221 on June 4, 2027 and 217 on June 5, 2028. F3 Price reflects a weighted average sale price for multiple transactions ranging from $258.02 to $258.03 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2026-08-12 | 2026-08-12 | Sohi Mohsen | Director | $957k | S — Open-market saleForm 4 footnoteF1 Price reflects a weighted average sale price for multiple transactions ranging from $235.73 to $235.89 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2026-03-05 | 2026-03-06 | Feldmann Cynthia L | Director | $735k | S — Open-market saleForm 4 footnoteF1 Price reflects a weighted average sale price for multiple transactions ranging from $237.16 to $237.33 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2026-06-04 | 2026-06-08 | Carestio Daniel A | President and CEO | $656k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-06-02 | 2026-06-04 | Breeden Richard C | Director | $310k | S — Open-market saleForm 4 footnoteF1 Price reflects a weighted average sale price for multiple transactions ranging from $209.50 to $209.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. | SEC |
| 2026-06-15 | 2026-06-16 | Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | $297k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 As of June 15, 2026, 8,239 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,453 on June 2, 2027; 1,252 on June 3, 2027; 1,376 on June 4, 2027; 1,453 on June 2, 2028; 1,252 on June 5, 2028 and 1,453 on June 4, 2029. | SEC |
| 2026-06-05 | 2026-06-08 | Carestio Daniel A | President and CEO | $291k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF2 As of June 8, 2026, 39,893 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 7,912 on June 2, 2027; 5,937 on June 3, 2027; 4,283 on June 4, 2027; 7,912 on June 2, 2028; 5,937 on June 5, 2028 and 7,912 on June 4, 2029. | SEC |
| 2025-10-06 | 2025-10-08 | Carestio Daniel A | President and CEO | $38k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 As of October 6, 2025, 33,054 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 4,308 on June 1, 2026; 5,937 on June 3, 2026; 2,369 on June 2, 2026; 4,283 on June 4, 2026; 5,937 on June 3, 2027; 4,283 on June 4, 2027; and 5,937 on June 5, 2028. | SEC |
| 2025-11-11 | 2025-11-13 | Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | $1.0M | M — Option exerciseForm 4 footnoteF1 As of November 11, 2025, 8,511 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,157 on June 1, 2026; 846 on June 2, 2026; 1,252 on June 3, 2026; 1,376 on June 4, 2026; 1,252 on June 3 2027; 1,376 on June 4, 2027 and 1,252 on June 5, 2028. | SEC |
| 2025-11-18 | 2025-11-20 | Tamaro Renato | V.P. & Corporate Treasurer | $644k | M — Option exerciseForm 4 footnoteF1 As of November 18, 2025, 1,475 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 241 on June 1, 2026; 141 on June 2, 2026; 217 on June 3, 2026; 221 on June 4, 2026; 217 on June 3, 2027; 221 on June 4, 2027 and 217 on June 5, 2028. | SEC |
| 2025-11-21 | 2025-11-25 | Madsen Julia | Sr. VP and GM, Life Sciences | $642k | M — Option exerciseForm 4 footnoteF1 As of November 21, 2025, 4,003 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 578 on June 1, 2026, 352 on June 2, 2026; 666 on June 3, 2026; 542 on June 4, 2026; 666 on June 3, 2027; 542 on June 4, 2027 and 666 on June 5, 2028. | SEC |
| 2026-06-03 | 2026-06-05 | Carestio Daniel A | President and CEO | $550k | F — Tax withholding (shares surrendered for taxes)2 Form 4 footnotesF1 2,619 shares were withheld from the 5,937 restricted shares that vested on June 3, 2026. These 2,619 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These vested shares were valued at the NYSE closing market price on June 3, 2026. F2 As of June 3, 2026, 44,176 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 4,283 on June 4, 2026; 7,912 on June 2, 2027; 5,937 on June 3, 2027; 4,283 on June 4, 2027; 7,912 on June 2, 2028; 5,937 on June 5, 2028 and 7,912 on June 4, 2029. | SEC |
| 2026-03-05 | 2026-03-06 | Feldmann Cynthia L | Director | $472k | M — Option exercise | SEC |
| 2026-06-04 | 2026-06-08 | Carestio Daniel A | President and CEO | $401k | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1)Form 4 footnoteF1 1,889 shares were withheld from the 4,283 restricted shares that vested on June 4, 2026. These 1,889 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These vested shares were valued at the NYSE closing market price on June 4, 2026. | SEC |
| 2026-07-01 | 2026-07-02 | Sohi Mohsen | Director | $390k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Net - Cashless Stock Option Exercise - Options to purchase 1,837 shares were surrendered to the Company for payment of the option price. Options surrendered were valued based on the Company stock closing market price on the NYSE on the day on which the Net - Cashless Stock Option Exercise occurred. | SEC |
| 2026-08-12 | 2026-08-12 | Sohi Mohsen | Director | $350k | M — Option exercise | SEC |
| 2026-07-01 | 2026-07-02 | Sohi Mohsen | Director | $270k | M — Option exercise | SEC |
| 2026-06-02 | 2026-06-04 | Breeden Richard C | Director | $270k | M — Option exercise | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Oct 3, 2025 and Oct 5, 2026 there is not one open-market purchase of STERIS plc: 10 sales worth $9.9M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like STERIS plc's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 40 | $2.5M |
| A | Grant or award | 11 | $0 |
| S | Open-market sale | 10 | $9.9M |
| M | Option exercise | 8 | $3.7M |
| Total | Everything filed in the period | 69 | $16.0M |
28 of the 69 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 12 distinct people or entities have filed STERIS plc transactions: none bought on the open market and 7 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 7 who sold on the open market (10 sales in all), the three biggest sellers account for $6.9M of the $9.9M: 70% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Zangerle John Adam | Sr. VP, Gen Counsel, and Sec. | 9 | — | $4.3M (2) | 2026-06-16 |
| Madsen Julia | Sr. VP and GM, Life Sciences | 8 | — | $1.3M (1) | 2026-06-08 |
| Tamaro Renato | V.P. & Corporate Treasurer | 8 | — | $1.3M (1) | 2026-06-08 |
| Carestio Daniel A | President and CEO | 9 | — | $985k (3) | 2026-06-08 |
| Sohi Mohsen | Director | 4 | — | $957k (1) | 2026-08-12 |
| Feldmann Cynthia L | Director | 2 | — | $735k (1) | 2026-03-06 |
| Breeden Richard C | Director | 2 | — | $310k (1) | 2026-06-04 |
| Burton Karen L | Sr. Vice Pres., CFO | 8 | — | — | 2026-10-05 |
Shown here are the 8 who moved the most money, out of 12. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Jun 2026: 0 purchases and 4 sales, worth $1.6M. 10 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 1 | $38k |
| Nov 2025 | 0 | $0 | 3 | $6.6M |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 0 | $0 | 1 | $735k |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 4 | $1.6M |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 1 | $957k |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
STERIS plc (STE) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
4 of the 10 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. STERIS has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 5, 2026, and a Form 4 arrives up to two business days after the trade.
15 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.